Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | MMP2 | P08253 | 4/20 | 0.36 |
| ▸ | MMP9 | P14780 | 4/20 | 0.36 |
| ▸ | MMP1 | P03956 | 2/20 | 0.36 |
| ▸ | MMP8 | P22894 | 2/20 | 0.36 |
| ▸ | MMP13 | P45452 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5130366 | 0.95 | CA1 (0.34) | CA1CA2MMP2MMP9MMP1 | |
| SCHEMBL3349012 | 0.83 | F2 (0.39) | CA1CA2MMP2MMP9MMP1 | |
| SCHEMBL28243176 | 0.82 | ALDH1A1 (0.34) | CA1CA2MMP2MMP9MMP1 | |
| SCHEMBL31513699 | 0.82 | EPHX1 (0.42) | CA1CA2MMP2MMP9MMP8 | |
| SCHEMBL28004790 | 0.81 | CA2 (0.55) | CA1CA2MMP2MMP9MMP1 | |
| SCHEMBL28004789 | 0.81 | CA2 (0.55) | CA1CA2MMP2MMP9MMP1 | |
| SCHEMBL20906396 | 0.77 | ALDH1A1 (0.46) | CA1CA2MMP2MMP9MMP1 | |
| SCHEMBL20906397 | 0.77 | ALDH1A1 (0.46) | CA1CA2MMP2MMP9MMP1 | |
| SCHEMBL28005180 | 0.77 | ALDH1A1 (0.46) | CA1CA2MMP2MMP9MMP1 | |
| SCHEMBL24108521 | 0.75 | ITGB3 (0.39) | MMP2MMP9SMN1; SMN2TGFBR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049101-A1 | TOPICAL TREATMENT OF SKIN CANCER USING OLIGOPEPTIDES | BACOBA AG (CH) | 2026-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049101-A1 | TOPICAL TREATMENT OF SKIN CANCER USING OLIGOPEPTIDES | NGLY1, MC1R, EGFR | CA1 2893/4885CA2 1350/4885MMP2 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.